mitoxantrone has been researched along with Adverse Drug Event in 8 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase III trial in 1996." | 2.80 | Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. ( Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA, 2015) |
| "Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response." | 2.75 | Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ( Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H, 2010) |
| " Nine patients were enrolled at increasing dosage levels of ara-C (8, 12, and 16 g/m2 per dose level)." | 2.73 | Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). ( Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N, 2007) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Green, AK | 1 |
| Corty, RW | 1 |
| Wood, WA | 1 |
| Meeneghan, M | 1 |
| Reeder-Hayes, KE | 1 |
| Basch, E | 1 |
| Milowsky, MI | 1 |
| Dusetzina, SB | 1 |
| O'Brien, MM | 1 |
| Lacayo, NJ | 1 |
| Lum, BL | 1 |
| Kshirsagar, S | 1 |
| Buck, S | 1 |
| Ravindranath, Y | 1 |
| Bernstein, M | 1 |
| Weinstein, H | 1 |
| Chang, MN | 1 |
| Arceci, RJ | 1 |
| Sikic, BI | 1 |
| Dahl, GV | 1 |
| Shvidel, L | 1 |
| Shtalrid, M | 1 |
| Bairey, O | 1 |
| Rahimi-Levene, N | 1 |
| Lugassy, G | 1 |
| Shpilberg, O | 1 |
| Polliack, A | 1 |
| Berrebi, A | 1 |
| Pratt, RG | 1 |
| Boehm, GA | 1 |
| Kortepeter, CM | 1 |
| Racoosin, JA | 1 |
| Miyawaki, S | 1 |
| Kawai, Y | 1 |
| Takeshita, A | 1 |
| Komatsu, N | 1 |
| Usui, N | 1 |
| Arai, Y | 1 |
| Ishida, F | 1 |
| Morii, T | 1 |
| Kano, Y | 1 |
| Ogura, M | 1 |
| Doki, N | 1 |
| Ohno, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA[NCT00002912] | Phase 1 | 3 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for mitoxantrone and Adverse Drug Event
| Article | Year |
|---|---|
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, | 2015 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam | 2010 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Ef | 2007 |
5 other studies available for mitoxantrone and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2003 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Analgesics; Cardiomyopathies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Advers | 2005 |